Visualizing Global Attitudes Towards COVID-19 Vaccines
View the high-resolution of the infographic by clicking here.
To vaccinate, or not to vaccinate? That is the question.
In order to achieve herd immunity against COVID-19, some experts believe that between 70% to 80% of a population must be vaccinated.
But attitudes towards these vaccines are undoubtedly mixed. In fact, it’s estimated that one-third of people globally have some major concerns.
Using survey data from eight different countries, Global Web Index created five archetypes to help illustrate how typical attitudes towards vaccines differ depending on a range of factors, such as age, income, lifestyle, and values.
|Segment||Breakdown||Age Skew||Gender Skew||Income||Vaccine Concerns|
|Vaccine Supporter||66%||18-34||None||High income||Potential side-effects, availability, and logistics of vaccine distribution.|
|Vaccines Hesitant||12%||38-56||Female||Low/Middle income||Potential side-effects specifically due to no long-term testing, cost of vaccine, and more transparency around science required.|
|Vaccine Obligated||11%||16-24||Male||Low income||Potential side-effects, not sure COVID-19 vaccine is necessary to combat the virus.|
|Vaccine Skeptical||11%||45-64||Female||Low income||Potential side-effects, don’t believe vaccines can curtail the pandemic.|
|Anti-vaxxer||1.4% (13% of the Vaccine Skeptical segment)||16-24, 55-64||Male||Low income||Potential side-effects, don’t believe vaccines in general are safe.|
Countries surveyed: United States, Germany, United Kingdom, Brazil, China, India, Japan, and Italy.
Which segment are you most likely to fall under, according to these segments?
[People who say they will get the COVID-19 vaccine.]
Out of all participants surveyed, 66% of them support the idea of getting a COVID-19 vaccine. Within this group, there is a skew towards younger people (aged 18-34) who are likely working professionals earning a high income and living in a city.
Despite their optimism towards COVID-19 vaccines, however, one-third of vaccine supporters say they will wait to get one, due to lingering concerns regarding issues with vaccine distribution and any potential side-effects.
Interestingly, this procrastination mindset has been seen before during the H1N1 (swine flu) pandemic when both members of the general public and healthcare workers showed low levels of vaccine acceptance due to safety concerns.
[People who are not sure if they will get the COVID-19 vaccine.]
The vaccine hesitant group, which is more common among cautious suburban parents, makes up 12% of the total study. They are more likely to be female, and feel anxious about the length of time spent testing vaccines and therefore require more transparency around the science.
With that being said, this group could be easily swayed, as they are more receptive to word-of-mouth and messaging boards to get advice from their peers over any other medium.
[People who will only get the vaccine if it’s necessary for travel, school, work etc.]
The vaccine obligated group makes up 11% of the total, and has a skew towards males aged between 16 and 24 years old.
While this group is also concerned with potential side-effects, their responses suggesting that a vaccine may not be necessary to combat COVID-19 was above average compared to other segments in the study. They also index above average when it comes to viewing themselves as traditionalists.
[People who won’t get the COVID-19 vaccine.]
The vaccine skeptical group makes up another 11% of the total. However, this group is mostly female, who are aged between 45-64 and earn a lower-than-average income. They are less likely to have a college degree, and are more likely to live in a rural area.
Along with the worry of potential side-effects, this group is generally more pessimistic about containing COVID-19 at all. Therefore a small percentage do not believe a vaccine will help tackle the global health crisis.
With notably low trust levels, this group is one of the hardest to reach and potentially persuade. What makes them unique however, is their lack of faith in the scientific process.
[People who will not get the vaccine, because they are against vaccines in general.]
It is important to note that those who choose not to get a COVID-19 vaccine should not be confused with anti-vaxxers.
Anti-vaxxers are a sub-segment of the vaccine skeptical group that makes up 1.4% of the total population. The difference is, anti-vaxxers do not believe in getting any vaccine due to safety concerns, not just not a vaccine for COVID-19.
According to the study, anti-vaxxers tend to fall into one of two age brackets, between 16-24 years or 55-64 years old, and are typically males with lower incomes.
Another Tool in the Arsenal Against COVID-19
The study demonstrates that broad segments of society—regardless of their demographic or views—are at least somewhat concerned about COVID-19 vaccines becoming widely available.
While scientists are not quite sure if the current vaccines on the market can stop infection or transmission of the virus, they are an important part of our global defenses against COVID-19, along with other safety restrictions like wearing masks and keeping a distance.
Explainer: What to Know About Monkeypox
What is monkeypox, and what risk does it pose to the public? This infographic breaks down the symptoms, transmission, and more.
Explainer: What to Know About Monkeypox
The COVID-19 pandemic is still fresh in the minds of the people around the world, so it comes as no surprise that recent outbreaks of another virus are grabbing headlines.
Monkeypox outbreaks have now been reported in multiple countries, and it has scientists paying close attention. For everyone else, numerous questions come to the surface:
- How serious is this virus?
- How contagious is it?
- Could monkeypox develop into a new pandemic?
Below, we answer these questions and more.
What is Monkeypox?
Monkeypox is a virus in the Orthopoxvirus genus which also includes the variola virus (which causes smallpox) and the cowpox virus. The primary symptoms include fever, swollen lymph nodes, and a distinctive bumpy rash.
There are two major strains of the virus that pose very different risks:
- Congo Basin strain: 1 in 10 people infected with this strain have died
- West African strain: Approximately 1 in 100 people infected with this strain died
At the moment, health authorities in the UK have indicated they’re seeing the milder strain in patients there.
Where did Monkeypox Originate From?
The virus was originally discovered in the Democratic Republic of Congo in monkeys kept for research purposes (hence the name). Eventually, the virus made the jump to humans more than a decade after its discovery in 1958.
It is widely assumed that vaccination against another similar virus, smallpox, helped keep monkeypox outbreaks from occurring in human populations. Ironically, the successful eradication of smallpox, and eventual winding down of that vaccine program, has opened the door to a new viral threat. There is now a growing population of people who no longer have immunity against the virus.
Now that travel restrictions are lifting in many parts of the world, viruses are now able to hop between nations again. As of the publishing of this article, a handful of cases have now been reported in the U.S., Canada, the UK, and a number of European countries.
On the upside, contact tracing has helped authorities piece together the transmission of the virus. While cases are rare in Europe and North America, it is considered endemic in parts of West Africa. For example, the World Health Organization reports that Nigeria has experienced over 550 reported monkeypox cases from 2017 to today. The current UK outbreak originated from an individual who returned from a trip to Nigeria.
Could Monkeypox become a new pandemic?
Monkeypox, which primarily spreads through animal-to-human interaction, is not known to spread easily between humans. Most individuals infected with monkeypox pass the virus to between zero and one person, so outbreaks typically fizzle out. For this reason, the fact that outbreaks are occurring in several countries simultaneously is concerning for health authorities and organizations that monitor viral transmission. Experts are entertaining the possibility that the virus’ rate of transmission has increased.
Images of people covered in monkeypox lesions are shocking, and people are understandably concerned by this virus, but the good news is that members of the general public have little to fear at this stage.
I think the risk to the general public at this point, from the information we have, is very, very low.
–Tom Inglesby, Director, Johns Hopkins Center for Health Security
» For up-to-date information on monkeypox cases, check out Global.Health’s tracking spreadsheet
Visualizing How COVID-19 Antiviral Pills and Vaccines Work at the Cellular Level
Despite tackling the same disease, vaccines and antiviral pills work differently to combat COVID-19. We visualize how they work in the body.
Current Strategies to Tackle COVID-19
Since the pandemic started in 2020, a number of therapies have been developed to combat COVID-19.
The leading options for preventing infection include social distancing, mask-wearing, and vaccination. They are still recommended during the upsurge of the coronavirus’s latest mutation, the Omicron variant.
But in December 2021, The United States Food and Drug Administration (USDA) granted Emergency Use Authorization to two experimental pills for the treatment of new COVID-19 cases.
These medications, one made by Pfizer and the other by Merck & Co., hope to contribute to the fight against the coronavirus and its variants. Alongside vaccinations, they may help to curb extreme cases of COVID-19 by reducing the need for hospitalization.
Despite tackling the same disease, vaccines and pills work differently:
|Taken by injection||Taken by mouth|
|Used for prevention||Used for treatment only|
|Create an enhanced immune system by stimulating antibody production||Disrupt the assembly of new viral particles|
How a Vaccine Helps Prevent COVID-19
The main purpose of a vaccine is to prewarn the body of a potential COVID-19 infection by creating antibodies that target and destroy the coronavirus.
In order to do this, the immune system needs an antigen.
It’s difficult to do this risk-free since all antigens exist directly on a virus. Luckily, vaccines safely expose antigens to our immune systems without the dangerous parts of the virus.
In the case of COVID-19, the coronavirus’s antigen is the spike protein that covers its outer surface. Vaccines inject antigen-building instructions* and use our own cellular machinery to build the coronavirus antigen from scratch.
When exposed to the spike protein, the immune system begins to assemble antigen-specific antibodies. These antibodies wait for the opportunity to attack the real spike protein when a coronavirus enters the body. Since antibodies decrease over time, booster immunizations help to maintain a strong line of defense.
*While different vaccine technologies exist, they all do a similar thing: introduce an antigen and build a stronger immune system.
How COVID Antiviral Pills Work
Antiviral pills, unlike vaccines, are not a preventative strategy. Instead, they treat an infected individual experiencing symptoms from the virus.
These medications disrupt specific processes in the viral assembly line to choke the virus’s ability to replicate.
The Mechanism of Molnupiravir
RNA-dependent RNA Polymerase (RdRp) is a cellular component that works similar to a photocopying machine for the virus’s genetic instructions. An infected host cell is forced to produce RdRp, which starts generating more copies of the virus’s RNA.
Molnupiravir, developed by Merck & Co., is a polymerase inhibitor. It inserts itself into the viral instructions that RdRp is copying, jumbling the contents. The RdRp then produces junk.
The Mechanism of Nirmatrelvir + Ritonavir
A replicating virus makes proteins necessary for its survival in a large, clumped mass called a polyprotein. A cellular component called a protease cuts a virus’s polyprotein into smaller, workable pieces.
Pfizer’s antiviral medication is a protease inhibitor made of two pills:
- The first pill, nirmatrelvir, stops protease from cutting viral products into smaller pieces.
- The second pill, ritonavir, protects nirmatrelvir from destruction by the body and allows it to keep working.
With a faulty polymerase or a large, unusable polyprotein, antiviral medications make it difficult for the coronavirus to replicate. If treated early enough, they can lessen the virus’s impact on the body.
The Future of COVID Antiviral Pills and Medications
Antiviral medications seem to have a bright future ahead of them.
COVID-19 antivirals are based on early research done on coronaviruses from the 2002-04 SARS-CoV and the 2012 MERS-CoV outbreaks. Current breakthroughs in this technology may pave the way for better pharmaceuticals in the future.
One half of Pfizer’s medication, ritonavir, currently treats many other viruses including HIV/AIDS.
Gilead Science is currently developing oral derivatives of remdesivir, another polymerase inhibitor currently only offered to inpatients in the United States.
More coronavirus antivirals are currently in the pipeline, offering a glimpse of control on the looming presence of COVID-19.
Author’s Note: The medical information in this article is an information resource only, and is not to be used or relied on for any diagnostic or treatment purposes. Please talk to your doctor before undergoing any treatment for COVID-19. If you become sick and believe you may have symptoms of COVID-19, please follow the CDC guidelines.
Misc1 week ago
The Top 10 Largest Nuclear Explosions, Visualized
Technology4 weeks ago
How Do Big Tech Giants Make Their Billions?
Energy2 weeks ago
Mapped: Solar and Wind Power by Country
Datastream4 weeks ago
Visualizing Companies with the Most Patents Granted in 2021
Politics2 weeks ago
Mapped: The State of Global Democracy in 2022
Technology2 weeks ago
Synthetic Biology: The $3.6 Trillion Science Changing Life as We Know It
Markets3 weeks ago
Why Investors Tuned Out Netflix
Markets3 weeks ago
Charted: U.S. Consumer Debt Approaches $16 Trillion